CAS 105026-50-4

morfolinoantraciclina MX2

Descrizione:

morfolinoantraciclina MX2, con il numero CAS 105026-50-4, è un derivato sintetico dell'antraciclina, una classe di composti noti per le loro potenti proprietà antitumorali. Questo composto presenta un gruppo morfolino, che ne migliora la solubilità e potenzialmente altera il suo profilo farmacocinetico rispetto alle antracicline tradizionali. morfolinoantraciclina MX2 mostra un meccanismo d'azione che tipicamente coinvolge l'intercalazione nel DNA, portando a una interruzione dei processi di replicazione e trascrizione, inducendo infine l'apoptosi nelle cellule tumorali. Le sue modifiche strutturali mirano a migliorare la selettività e ridurre la cardiotossicità, un effetto collaterale comune associato alle antracicline convenzionali. Il composto è principalmente studiato per la sua efficacia contro varie malignità, e la ricerca in corso si concentra sul suo potenziale terapeutico, sui regimi di dosaggio ottimali e sui profili degli effetti collaterali. Come per molti agenti chemioterapici, comprendere la sua farmacodinamica e farmacocinetica è cruciale per massimizzare i suoi benefici clinici riducendo al minimo gli effetti avversi.

Formula: C₃₀H₃₅NO₁₁

InChI: InChI=1S/C30H35NO11/c1-3-30(39)12-17(42-18-11-15(24(33)13(2)41-18)31-7-9-40-10-8-31)20-23(29(30)38)28(37)21-22(27(20)36)26(35)19-14(25(21)34)5-4-6-16(19)32/h4-6,13,15,17-18,24,29,32-33,36-39H,3,7-12H2,1-2H3

InChI key: InChIKey=OPBPMGYBSDKJBT-UHFFFAOYSA-N

SMILES: OC=1C2=C(C(OC3CC(C(O)C(C)O3)N4CCOCC4)CC(CC)(O)C2O)C(O)=C5C1C(=O)C=6C(C5=O)=C(O)C=CC6

Sinonimi:

• (7R,8R,10S)-8-Ethyl-7,8,9,10-tetrahydro-1,6,7,8,11-pentahydroxy-10-[[2,3,6-trideoxy-3-(4-morpholinyl)-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione
• (7S-9R,10R)-3'-Deamino-3'-(4-morpholinyl)-13-deoxy-10-hydroxycarminomycin
• 3-Ethyl-3,4,5,10,12-Pentahydroxy-6,11-Dioxo-1,2,3,4,6,11-Hexahydrotetracen-1-Yl 2,3,6-Trideoxy-3-Morpholin-4-Ylhexopyranoside
• 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-8-ethyl-10-((3-(4-morpholinyl)-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-1,6,7,8,11-pentahydroxy-
• 5,12-Naphthacenedione, 8-ethyl-7,8,9,10-tetrahydro-1,6,7,8,11-pentahydroxy-10-((2,3,6-trideoxy-3-(4-morpholinyl)-alpha-L-lyxo-hexopyranosyl)oxy)-
• 5,12-Naphthacenedione, 8-ethyl-7,8,9,10-tetrahydro-1,6,7,8,11-pentahydroxy-10-[[2,3,6-trideoxy-3-(4-morpholinyl)-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl]oxy]-, (7R,8R,10S)-
• Antibiotic MX 2
• MX 2 (anthracycline)
• Morpholinyl oxaunomycin
• Mx 2
• [7S,9R,10R]-3′-Deamino-3′-(4-morpholinyl)-13-deoxo-10-hydroxycarminomycin
• 5,12-Naphthacenedione, 8-ethyl-7,8,9,10-tetrahydro-1,6,7,8,11-pentahydroxy-10-[[2,3,6-trideoxy-3-(4-morpholinyl)-α-L-lyxo-hexopyranosyl]oxy]-, (7R,8R,10S)-
• Morpholinoanthracycline MX2

Anthracycline

CAS: 105026-50-4

Anthracycline is a class of chemotherapy drugs, which are anthraquinone antibiotics derived from the bacterial genus Streptomyces. They exert their therapeutic effects primarily through intercalation into DNA, disrupting the function of enzymes such as topoisomerase II, thus preventing the transcription and replication processes in rapidly dividing cancer cells. Furthermore, they generate free radicals, leading to oxidative stress and subsequent cell damage. These mechanisms collectively result in apoptosis of malignant cells. Anthracyclines are utilized extensively in oncology for the treatment of various malignancies, including leukemias, lymphomas, breast cancer, and sarcomas. The efficacy of anthracyclines in inhibiting tumor growth must be balanced against their cardiotoxic potential, which is a significant consideration in their clinical use. This dual nature makes them both pivotal and challenging in chemotherapy regimens, necessitating careful management and monitoring throughout treatment.

Formula: C₃₀H₃₅NO₁₁

Purezza: Min. 95%

Peso molecolare: 585.60 g/mol

Ref: 3D-FA29742